392 related articles for article (PubMed ID: 17666915)
1. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
2. [Effect of valsartan on postprandial plasma inflammatory factors in patients with essential hypertension].
Liu L; Zhao SP; Zhou HN; Xu DY; Li JX
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 33(9):809-13. PubMed ID: 18812659
[TBL] [Abstract][Full Text] [Related]
3. Postprandial hypertriglyceridemia associated with inflammatory response and procoagulant state after a high-fat meal in hypertensive patients.
Liu L; Zhao SP; Wen T; Zhou HN; Hu M; Li JX
Coron Artery Dis; 2008 May; 19(3):145-51. PubMed ID: 18418230
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin blunts the effect of a high-fat meal on plasma triglyceride and high-sensitivity C-reactive protein concentrations in patients at high risk for cardiovascular events.
Liu L; Zhao SP; Hu M; Li JX
Coron Artery Dis; 2007 Sep; 18(6):489-93. PubMed ID: 17700222
[TBL] [Abstract][Full Text] [Related]
5. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Fogari R; Derosa G; Lazzari P; Zoppi A; Fogari E; Rinaldi A; Mugellini A
Am J Hypertens; 2004 Sep; 17(9):823-7. PubMed ID: 15363826
[TBL] [Abstract][Full Text] [Related]
6. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
7. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells.
Mussoni L; Banfi C; Sironi L; Arpaia M; Tremoli E
Thromb Haemost; 2000 Jul; 84(1):59-64. PubMed ID: 10928471
[TBL] [Abstract][Full Text] [Related]
9. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
11. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
13. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
[TBL] [Abstract][Full Text] [Related]
15. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
16. Effects of cilnidipine on lipids, lipoproteins and fibrinolytic system in hypertensive patients.
Ahaneku JE; Sakata K; Uranol T; Takada Y; Takada A
Drugs Exp Clin Res; 2000; 26(4):119-23. PubMed ID: 11109511
[TBL] [Abstract][Full Text] [Related]
17. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
Conen D; Everett BM; Glynn RJ; Ridker PM
Heart; 2008 Mar; 94(3):e13. PubMed ID: 17923463
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
19. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
Horiuchi M; Cui TX; Li Z; Li JM; Nakagami H; Iwai M
Circulation; 2003 Jan; 107(1):106-12. PubMed ID: 12515751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
